GB9507929D0 - Safety enhancing compositions of an active indazole - Google Patents

Safety enhancing compositions of an active indazole

Info

Publication number
GB9507929D0
GB9507929D0 GBGB9507929.9A GB9507929A GB9507929D0 GB 9507929 D0 GB9507929 D0 GB 9507929D0 GB 9507929 A GB9507929 A GB 9507929A GB 9507929 D0 GB9507929 D0 GB 9507929D0
Authority
GB
United Kingdom
Prior art keywords
enhancing compositions
safety enhancing
indazole
active
active indazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB9507929.9A
Other versions
GB2291591A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
REDPATH TREVOR H
Original Assignee
REDPATH TREVOR H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by REDPATH TREVOR H filed Critical REDPATH TREVOR H
Priority to GB9822737A priority Critical patent/GB2327191A/en
Publication of GB9507929D0 publication Critical patent/GB9507929D0/en
Publication of GB2291591A publication Critical patent/GB2291591A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB9507929A 1994-06-28 1995-04-19 Pharmaceutical uses of granisetron Withdrawn GB2291591A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9822737A GB2327191A (en) 1994-06-28 1995-04-19 Pharmaceutical uses of granisetron

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9412995A GB9412995D0 (en) 1994-06-28 1994-06-28 Safety enhancing pharmaceutical compositions of an active indazole

Publications (2)

Publication Number Publication Date
GB9507929D0 true GB9507929D0 (en) 1995-06-14
GB2291591A GB2291591A (en) 1996-01-31

Family

ID=10757464

Family Applications (2)

Application Number Title Priority Date Filing Date
GB9412995A Pending GB9412995D0 (en) 1994-06-28 1994-06-28 Safety enhancing pharmaceutical compositions of an active indazole
GB9507929A Withdrawn GB2291591A (en) 1994-06-28 1995-04-19 Pharmaceutical uses of granisetron

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB9412995A Pending GB9412995D0 (en) 1994-06-28 1994-06-28 Safety enhancing pharmaceutical compositions of an active indazole

Country Status (1)

Country Link
GB (2) GB9412995D0 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU759250B2 (en) * 1998-12-22 2003-04-10 Novartis Pharma Gmbh Use of 5HT3-receptor antagonists for the treatment of chronic fatigue syndrome
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3687080T2 (en) * 1985-04-27 1993-03-25 Beecham Group Plc AZABICYCLONONYL INDAZOL CARBOXAMIDE WITH 5-HT ANTAGONISTIC EFFECT.
ATE124865T1 (en) * 1986-12-17 1995-07-15 Glaxo Group Ltd USE OF HETEROCYCLIC COMPOUNDS TO TREAT DISORDERS OF CONSCIOUSNESS.
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals

Also Published As

Publication number Publication date
GB9412995D0 (en) 1994-10-26
GB2291591A (en) 1996-01-31

Similar Documents

Publication Publication Date Title
PL325972A1 (en) Compositions for and methods of fighting against harmful fungi
ZA945653B (en) Therapeutic compositions
IL115498A0 (en) Substituted alkyl 1-phenylalkyl-4-hydroxy-2-oxo- 1,8-naphthyridine-3-carboxylates their preparation and therapeutic compositions containing them
GB9422280D0 (en) Fluorescent whitening agent formulation
PL318586A1 (en) Combination of auxiliary components ensuring selective release of active component
NZ318391A (en) Fungicidal compositions comprising fenazaquine as an active substance
PL340305A1 (en) Composition of agents reducing the level of lipoides
PL327329A1 (en) Aqueous compositions of silicates
PL323594A1 (en) Compositions for fighting against parasitic protozoa
ZA957113B (en) Use of N-substituted pyhenothiazines
SG68529A1 (en) The use of des-aspartate-angiotensin i (agr-val-tyr-ile-his-pro-phe-his-leu) as an anti-cardiac hypertrophic agent
GB9405229D0 (en) Compositions of matter
IL112564A0 (en) 1-beta-methyl-carbapenems and compositions containing them
GB9507929D0 (en) Safety enhancing compositions of an active indazole
IL103907A0 (en) Ophthalmic compositions
EP0868430A4 (en) Therapeutic compositions
GB2294708B (en) Fluorescent whitening agent formulation
ZA962531B (en) Appliance for the discharge of crop protection agents
GB9816046D0 (en) Safety enhancing pharmeceutical compositions
GB9315223D0 (en) Intumescent compositions
PL316307A1 (en) Application of dimeticone
IL102984A0 (en) Ophthalmic compositions comprising pilocarpine
HUP9901162A3 (en) Compounds and compositions for delivering active agents
HU9403283D0 (en) Compositions of ditiocarbamat
ZA979098B (en) Ester compounds and harmful organism-controlling agents containing them as active ingredients

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)
711Q Appeals lodged - section 117
711R Appeal withdrawn - section 117